Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma

Blood

Volumn 122, Issue 6, 2013, Pages 863-871

  Linette, Gerald P ^a   Stadtmauer, Edward A ^b   Maus, Marcela V ^b   Rapoport, Aaron P ^c   Levine, Bruce L ^b   Emery, Lyndsey ^b   Litzky, Leslie ^b   Bagg, Adam ^b   Carreno, Beatriz M ^a   Cimino, Patrick J ^a   Binder Scholl, Gwendolyn K ^d   Smethurst, Dominic P ^d   Gerry, Andrew B ^d   Pumphrey, Nick J ^d   Bennett, Alan D ^d   Brewer, Joanna E ^d   Dukes, Joseph ^e   Harper, Jane ^e   Tayton Martin, Helen K ^d   Jakobsen, Bent K ^d,e   Hassan, Namir J ^e   Kalos, Michael ^b   June, Carl H ^b   more..

^a USA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d Adaptimmune Ltd   (United Kingdom)

^e Immunocore Limited   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BORTEZOMIB; CISPLATIN; CONNECTIN; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; HYDROCORTISONE; IPILIMUMAB; LENALIDOMIDE; MELANOMA ANTIGEN 3; MELPHALAN; METHYLPREDNISOLONE; T LYMPHOCYTE RECEPTOR; CYTOKINE; EPITOPE; HLA A ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; MAGEA3 PROTEIN, HUMAN; MUSCLE PROTEIN; PEPTIDE; PROTEIN KINASE; TUMOR ANTIGEN; TUMOR PROTEIN;

ACUTE HEART INFARCTION; ADOPTIVE TRANSFER; ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; AUTOPSY; BINDING AFFINITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOGENIC SHOCK; CARDIOPULMONARY ARREST; CARDIOTOXICITY; CASE REPORT; CELL CULTURE; CELL INFILTRATION; CELL KILLING; CELL PROLIFERATION; CELL THERAPY; CONTROLLED STUDY; CROSS REACTION; DISEASE COURSE; DISEASE SEVERITY; HEART MUSCLE CELL; HEART MUSCLE INJURY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MALE; MELANOMA; MYELOMA; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION PNEUMONIA; SENTINEL LYMPH NODE BIOPSY; ST SEGMENT ELEVATION; T LYMPHOCYTE; THORAX PAIN; WIDE EXCISION; ADOPTIVE IMMUNOTHERAPY; ALLELE; BLOOD; CARDIOVASCULAR DISEASE; CULTURE TECHNIQUE; CYTOLOGY; HEART MUSCLE; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MULTIPLE MYELOMA; PATHOLOGY; PROTEIN ENGINEERING; PROTEIN MOTIF;

ALLELES; AMINO ACID MOTIFS; ANTIGENS, NEOPLASM; CARDIOVASCULAR DISEASES; CELL CULTURE TECHNIQUES; CYTOKINES; EPITOPES; HLA-A ANTIGENS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INDUCED PLURIPOTENT STEM CELLS; MALE; MELANOMA; MIDDLE AGED; MULTIPLE MYELOMA; MUSCLE PROTEINS; MYOCARDIUM; NEOPLASM PROTEINS; PEPTIDES; PROTEIN ENGINEERING; PROTEIN KINASES; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 84880730689     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-03-490565     Document Type: Article

References (33)

1. Schumacher TN. T-cell-receptor gene therapy. Nat Rev Immunol. 2002; 2(7): 512-519. (Pubitemid 37328742)
2. Varela-Rohena A., Molloy PE, Dunn S.M., et al. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat Med. 2008; 14(12): 1390-1395. [Epub 2008 Nov 1399]
3. Robbins PF, Morgan RA, Feldman S.A., et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011; 29(7): 917-924.
4. Purbhoo MA, Sutton DH, Brewer J.E., et al. Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors. J Immunol. 2006; 176(12): 7308-7316. (Pubitemid 43849031)
5. Cameron BJ, Gerry AB, Dukes J, et al. Identification of titin as an alternative specificity for engineered T cells expressing an enhanced affinity MAGE A3 TCR. Sci Transl Med. In press.
6. Recombinant DNA Advisory Committee: Minutes of Meeting on June 19, 2012. http://oba.od.nih.gov/oba/RAC/meetings/June2012/RAC-Minutes-06-12.pdf. Accessed June 21, 2013.
7. Kalos M, Levine BL, Porter D.L., et al. T cells expressing chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011; 3(95): 95ra73.
8. Janetzki S, Britten CM, Kalos M, et al. "MIATA"-minimal information about T cell assays. Immunity. 2009; 31(4): 527-528.
9. Olson WC, Smolkin ME, Farris E.M., et al. Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function. J Transl Med. 2011; 9: 26.
10. Billingham ME, Cary NR, Hammond M.E., et al.; The International Society for Heart Transplantation. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. J Heart Transplant. 1990; 9(6): 587-593.
11. Stewart S, Winters GL, Fishbein M.C., et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005; 24(11): 1710-1720. (Pubitemid 41641841)
12. Bendle GM, Linnemann C, Hooijkaas A.I., et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med. 2010; 16(5): 565-570, 1p, 570.
13. LeWinter MM, Granzier H. Cardiac titin: a multifunctional giant. Circulation. 2010; 121(19): 2137-2145.
14. Herman DS, Lam L, Taylor M.R., et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med. 2012; 366(7): 619-628.
15. Cheever MA, Allison JP, Ferris A.S., et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009; 15(17): 5323-5337.
16. Simpson AJ, Caballero OL, Jungbluth A, Chen Y.T., Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005; 5(8): 615-625. (Pubitemid 41081387)
17. Rosenberg SA. Of mice, not men: no evidence for graft-versus-host disease in humans receiving T-cell receptor-transduced autologous T cells. Mol Ther. 2010; 18(10): 1744-1745.
18. Zhao Y, Bennett AD, Zheng Z, et al. High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines. J Immunol. 2007; 179(9): 5845-5854.
19. Yamamoto AM, Gajdos P, Eymard B., et al. Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients. Arch Neurol. 2001; 58(6): 885-890. (Pubitemid 32537462)
20. Manno CS, Chew AJ, Hutchison S, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood. 2003; 101(8): 2963-2972. (Pubitemid 36857981)
21. Manno CS, Pierce GF, Arruda V.R., et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006; 12(3): 342-347. (Pubitemid 43355084)
22. Tarrio ML, Grabie N, Bu D.X., Sharpe AH, Lichtman AH. PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J Immunol. 2012; 188(10): 4876-4884.
23. Matsumori A. Lessons learned from experimental myocarditis. Herz. 2012; 37(8): 817-821.
24. Connerotte T, Van Pel A, Godelaine D, et al. Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities. Cancer Res. 2008; 68(10): 3931-3940.
25. Morgan RA, Chinnasamy N, Abate-Daga D, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 2013; 36(2): 133-151.
26. Parkhurst MR, Yang JC, Langan R.C., et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2011; 19(3): 620-626.
27. Johnson LA, Morgan RA, Dudley M.E., et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009; 114(3): 535-546.
28. Morgan RA, Yang JC, Kitano M, Dudley M.E., Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010; 18(4): 843-851.
29. Porter DL, Levine BL, Kalos M, Bagg A., June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365(8): 725-733.
30. Grupp SA, Kalos M, Barrett D., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013; 368(16): 1509-1518.
31. Di Stasi A., Tey SK, Dotti G, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011; 365(18): 1673-1683.
32. Li Y, Moysey R, Molloy P.E., et al. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat Biotechnol. 2005; 23(3): 349-354. (Pubitemid 41094424)
33. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2012; 12(4): 269-281.